Balderrama-Soto A, Vergara-López A, Guillén-González MÁ, Joya-Galeana J, Ixcamparij-Rosales CH

Language: Spanish
References: 10
Page: 7-11
PDF size: 72.94 Kb.

ABSTRACT

Objective: To describe the echocardiographic abnormalities of patients with acromegaly treated at Centro Médico Nacional «20 de Noviembre». Materials and methods: Cross-sectional and observational study of patients with acromegaly attending our clinic between February and June 2010. All subjects underwent Doppler echocardiography; clinical and biochemical characteristics of those with and without echocardiographic abnormalities were compared. Results: Thirty-five patients, 22 women (62.8%) and 13 males (32.75%), with a mean age of 52.8 ± 13 years were studied; mean disease duration was 12.9 years. Transsphenoidal surgery had been performed in 28 of the patients (80%), while 7 were waiting surgical treatment. Echocardiography revealed hypertrophy of the septum and the posterior wall in 40%. Septum thickness positively correlated with disease duration (r = 0.38, p = 0.025), history of hypertension (r = 0.51, p = 0.002) and cavernous sinus invasion on MRI (r = 0.38, p = 0.025). Diastolic dysfunction was found in 54.28% of the patients and 40% had some degree of valvular involvement. The biochemical control of acromegaly did not correlate with the echocardiographic findings. Conclusions: As expected, 40% of our patients had echocardiographic abnormalities, concentric hypertrophy of the left ventricle being the most common one. Echocardiographic findings did not correlate with the degree of biochemical control, but disease duration did, suggesting that these abnormalities are the consequence of long-term exposure to hypersomatotropinemia.

REFERENCES

1. Colao A. The GH-IGF1 axis and the cardiovascular system: clinical implications. Clin Endocrinol 2008; 69: 347-358.

2. Lombardi G, Galdiero M, Auriemma RS, Pivonello R, Colao A. Acromegaly and the cardiovascular system. Neuroendocrinology 2006; 83: 211-217.

3. Vitale G, Pivonello R, Lombardi G, Colao A. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treat Endocrinol 2004; 3: 309-318.

4. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 2009; 94: 3746-3756.

5. Lie JT, Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Hearth J 1980; 100: 41-52.

6. Zlatareva N, Andreeva M, Angelova I. Echocardiografphic evaluation of left ventricular function in acromegaly patients (abstract). Endocrinologia (J Bulgarian Soc Endocrinol) 2000; 5: 3.

7. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Reversal of acromegalic cardiomyopathy in young but not in middle aged patients after 12 months of treatment with the depot long-acting somatostin analogue octreotide. Clin Endocrinol 2003; 58:169-176.

8. Clayton RN. Cardiovascular function in acromegaly. Endocr Rev 2003; 24: 272-277.

9. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008; 93: 2639-2646.

10. Bihan H, Espinosa C, Valdes-Socin H, Salenave S, Young J et al. Long term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 2004; 89: 5308-5313.